Polypeptides in treatment of patients with obliterating atherosclerosis of the arteries lower extremities

Introduction . Treatment of patients with chronic lower limb ischemia against the background of obliterating atherosclerosis should be aimed at restoring the impaired hemodynamics of the vascular bed. In atherosclerosis, a violation of the peptide composition leads to a decrease in the ability of the vascular wall to prevent the development of pathological processes. Aim . To evaluate the efficacy and safety of using a drug based on bovine vascular polypeptides in patients with obliterating atherosclerosis of the lower limb arteries. Materials and methods . 105 patients with chronic lower limb ischemia of grades IIA and IIB against the background of obliterating atherosclerosis. There were 96 men and 9 women, the average age was 60 ± 5.6 and 70 ± 3.8 years, respectively. All patients received conservative treatment. In the 1st group (n = 34) additionally – cilostazol; in the 2nd group (n = 35) – additionally sulodexide; in the 3rd (main) group (n = 36) – additionally – sulodexide according to the above scheme and Polipeptydi. Results . After 3 months from the start of treatment, a good therapeutic effect was maintained in all groups. After 6 months, negative dynamics were noted in the 1st and 2nd groups of patients. Repeated courses of conservative treatment were required. These patients were excluded from further study. In the 3rd group (Polipeptyd + sulodexide), the therapeutic effect was maintained for 9 months from the start of treatment. Discussion . If it is impossible to reconstruct arterial blood flow, it is necessary to prescribe drugs that increase the rheological properties of the blood, improve direct blood flow in the affected limb, and also have a positive effect on metabolism. Conclusions . The inclusion of Polipeptydm, a peptide regulator, in the complex conservative treatment of patients with obliterating atherosclerosis of the arteries of the extremities allows for an increase in its effectiveness and a significant prolongation of the positive therapeutic result.